{
    "body": "Which miRNAs could be used as potential biomarkers for epithelial ovarian cancer?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21345725", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22246341", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23888941", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23836287", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23542579", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23978303", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20035894", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19074899", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21571355", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18954897", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23918241", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21971665", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23272653", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23621186"
    ], 
    "ideal_answer": [
        "miR-200a, miR-100, miR-141, miR-200b, miR-200c, miR-203, miR-510, miR-509-5p, miR-132, miR-26a, let-7b, miR-145, miR-182, miR-152, miR-148a, let-7a, let-7i, miR-21, miR-92 and miR-93 could be used as potential biomarkers for epithelial ovarian cancer."
    ], 
    "exact_answer": [
        [
            "let-7a"
        ], 
        [
            "let-7b"
        ], 
        [
            "let-7i"
        ], 
        [
            "miR-21"
        ], 
        [
            "miR-26a"
        ], 
        [
            "miR-92"
        ], 
        [
            "miR-93"
        ], 
        [
            "miR-100"
        ], 
        [
            "miR-132"
        ], 
        [
            "miR-141"
        ], 
        [
            "miR-145"
        ], 
        [
            "miR-148a"
        ], 
        [
            "miR-152"
        ], 
        [
            "miR-182"
        ], 
        [
            "miR-200a"
        ], 
        [
            "miR-200b"
        ], 
        [
            "miR-200c"
        ], 
        [
            "miR-203"
        ], 
        [
            "miR-509-5p"
        ], 
        [
            "miR-510"
        ]
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035683", 
        "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015415", 
        "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010051", 
        "http://www.disease-ontology.org/api/metadata/DOID:2394"
    ], 
    "type": "list", 
    "id": "553fa78b1d53b76422000007", 
    "snippets": [
        {
            "offsetInBeginSection": 1010, 
            "offsetInEndSection": 1388, 
            "text": "Finally, five promising differentially miRNAs (miR-200a, miR-100, miR-141, miR-200b, and miR-200c) were reported with the consistent direction in four or more studies. MiR-200a, miR-200b, miR-200c, and miR-141, all of them belong to miR-200 family, were reported with consistently up-regulated in at least 4 studies, whereas miR-100 was reported with down-regulated in 4 studies", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23978303", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 122, 
            "text": "Upregulation of microRNA-203 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918241", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 1036, 
            "offsetInEndSection": 1418, 
            "text": "multivariate analysis showed that the status of miR-203 expression was an independent predictor for both overall survival and progression-free survival in EOC. These findings provide the convincing evidence for the first time that the upregulation of miR-203 may serve as a novel molecular marker to predict the aggressive tumor progression and unfavorable prognosis of EOC patients", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918241", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 493, 
            "offsetInEndSection": 773, 
            "text": "Some, but not all, of the data indicated that the miR-200 family was dysregulated in a variety of malignancies. In this study, we demonstrated that miR-200a and E-cadherin were significantly upregulated in EOC compared to benign epithelial ovarian cysts and normal ovarian tissues", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23888941", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1324, 
            "offsetInEndSection": 1656, 
            "text": "There was a significantly positive correlation between miR-200a and E-cadherin in EOC. The biphasic expression pattern suggested that miR-200a levels may serve as novel biomarkers for the early detection of EOC, and miR-200a and E-cadherin are candidate targets for the development of new treatment modalities against ovarian cancer", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23888941", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1385, 
            "offsetInEndSection": 1771, 
            "text": "Kaplan-Meier analysis showed low miR-510 expression, low miR-509-5p expression, and advanced FIGO stage, and chemotherapy resistance were significantly associated with poorer overall survival (P < 0.05). Our results suggest that miRNAs may play a role in the progression of OSC, and miR-510 and miR-509-5p may be considered novel-candidate clinical biomarkers for predicting OSC outcome", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23836287", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1158, 
            "offsetInEndSection": 1383, 
            "text": "The qRT-PCR results showed that miR-510, miR-509-5p, and miR-508-3p were significantly downregulated and that miR-483-5p was upregulated in stage III OSC compared with stage I, which was consistent with the microarray results", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23836287", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 138, 
            "offsetInEndSection": 704, 
            "text": "In this study, we examined serum miR-21 levels in epithelial ovarian cancer (EOC) patients, and explored its association with clinicopathological factors and prognosis. The results showed significantly higher serum miR-21 levels in EOC patients than in healthy controls. In addition, increased serum miR-21 expression was correlated with advanced FIGO stage, high tumor grade, and shortened overall survival. These findings indicate that serum miR-21 may serve as a novel diagnostic and prognostic marker, and be used as a therapeutic target for the treatment of EOC", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23621186", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 119, 
            "text": "Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23621186", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 1680, 
            "offsetInEndSection": 1813, 
            "text": "Serum miR-132, miR-26a, let-7b, and miR-145 could be considered as potential candidates as novel biomarkers in serous ovarian cancer.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23542579", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1173, 
            "offsetInEndSection": 1665, 
            "text": "Among the miRNAs that showed a consistent regulation tendency through all specimens and showed more than a 2-fold difference in serum, 5 miRNAs (miR-132, miR-26a, let-7b, miR-145, and miR-143) were determined as the 5 most markedly down-regulated miRNAs in the serum from ovarian cancer patients with respect to those of controls. Four miRNAs (miR-132, miR-26a, let-7b, and miR-145) out of 5 selected miRNAs were significantly underexpressed in the serum of ovarian cancer patients in qRT-PCR", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23542579", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 739, 
            "offsetInEndSection": 968, 
            "text": " microRNA (miR)-182, miR-200a, miR-200b and miR-200c were highly overexpressed in the SEOC cell lines relative to normal human ovarian surface epithelial cells and were assessed in RNA extracted from serum as candidate biomarkers", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23272653", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1426, 
            "offsetInEndSection": 1633, 
            "text": "Together, these results suggest that low miR-100 expression             may be an independent poor prognostic factor and miR-100 can function as a tumor             suppressor by targeting PLK1 in human EOCs", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22246341", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 111, 
            "text": "Prognostic implications of microRNA-100 and its functional roles in             human epithelial ovarian cancer", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22246341", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 1476, 
            "offsetInEndSection": 1738, 
            "text": "Taken together, miR-152 and miR-148a may be involved             in the carcinogenesis of ovarian cancer through deregulation of cell proliferation.             They may be novel biomarkers for early detection or therapeutic targets of ovarian             cancer", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21971665", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 92, 
            "text": "MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21571355", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 1988, 
            "offsetInEndSection": 2236, 
            "text": " The study suggests that the beneficial impact of the addition of paclitaxel on EOC survival was significantly linked to let-7a levels, and that miRNAs such as let-7a may be a useful marker for selection of chemotherapeutic agents in EOC management", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21571355", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 2573, 
            "offsetInEndSection": 2669, 
            "text": "miR-200c has potential as a predictor of survival, and is a biomarker of relapse, in stage I EOC", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21345725", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 116, 
            "text": "MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19074899", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 1507, 
            "offsetInEndSection": 1723, 
            "text": " our results strongly suggest that let-7i might be used as a therapeutic target to modulate platinum-based chemotherapy and as a biomarker to predict chemotherapy response and survival in patients with ovarian cancer", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19074899", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1560, 
            "offsetInEndSection": 1641, 
            "text": "miRNAs-21, 92 and 93 are known oncogenes with therapeutic and biomarker potential", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18954897", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1641, 
            "offsetInEndSection": 1773, 
            "text": "Serum miR-132, miR-26a, let-7b, and miR-145 could be considered as potential candidates as novel biomarkers in serous ovarian cancer", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23542579", 
            "endSection": "abstract"
        }
    ]
}